Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals by Daniels, Brian P et al.




Viral pathogen-associated molecular patterns
regulate blood-brain barrier integrity via competing
innate cytokine signals
Brian P. Daniels
Washington University School of Medicine in St. Louis
David W. Holman
Washington University School of Medicine in St. Louis
Lillian Cruz-Orengo
Washington University School of Medicine in St. Louis
Harsha Jujjavarapu
Washington University School of Medicine in St. Louis
Douglas M. Durrant
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Daniels, Brian P.; Holman, David W.; Cruz-Orengo, Lillian; Jujjavarapu, Harsha; Durrant, Douglas M.; and Klein, Robyn S., ,"Viral




Brian P. Daniels, David W. Holman, Lillian Cruz-Orengo, Harsha Jujjavarapu, Douglas M. Durrant, and
Robyn S. Klein
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/3239
doi:10.1128/mBio.01476-14.
 5(5): .mBio. Innate Cytokine Signals
Regulate Blood-Brain Barrier Integrity via Competing 
Viral Pathogen-Associated Molecular Patterns2014. 
al.




Integrity via Competing Innate Cytokine
Patterns Regulate Blood-Brain Barrier 
Viral Pathogen-Associated Molecular
 http://mbio.asm.org/content/5/5/e01476-14.full.html






This article cites 68 articles, 37 of which can be accessed free at:
CONTENT ALERTS
 more>>article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this
 
 http://journals.asm.org/subscriptions/To subscribe to another ASM Journal go to: 
 http://mbio.asm.org/misc/contentdelivery.xhtml
Information about Print on Demand and other content delivery options: 































Viral Pathogen-Associated Molecular Patterns Regulate Blood-Brain
Barrier Integrity via Competing Innate Cytokine Signals
Brian P. Daniels,a David W. Holman,b Lillian Cruz-Orengo,b Harsha Jujjavarapu,b Douglas M. Durrant,b Robyn S. Kleina,b,c
Department of Anatomy and Neurobiology,a Department of Internal Medicine,b and Department of Pathology and Immunology,c Washington University School of
Medicine, St. Louis, Missouri, USA
ABSTRACT Pattern recognition receptor (PRR) detection of pathogen-associated molecular patterns (PAMPs), such as viral RNA,
drives innate immune responses againstWest Nile virus (WNV), an emerging neurotropic pathogen. Here we demonstrate that
WNV PAMPs orchestrate endothelial responses toWNV via competing innate immune cytokine signals at the blood-brain bar-
rier (BBB), a multicellular interface with highly specialized brain endothelial cells that normally prevents pathogen entry. While
Th1 cytokines increase the permeability of endothelial barriers, type I interferon (IFN) promoted and stabilized BBB function.
Induction of innate cytokines by pattern recognition pathways directly regulated BBB permeability and tight junction formation
via balanced activation of the small GTPases Rac1 and RhoA, which in turn regulated the transendothelial trafficking ofWNV. In
vivo, mice with attenuated type I IFN signaling or IFN induction (Ifnar/ Irf7/) exhibited enhanced BBB permeability and
tight junction dysregulation afterWNV infection. Together, these data provide new insight into host-pathogen interactions at
the BBB during neurotropic viral infection.
IMPORTANCE West Nile virus (WNV) is an emerging pathogen capable of infecting the central nervous system (CNS), causing
fatal encephalitis. However, the mechanisms that control the ability ofWNV to cross the blood-brain barrier (BBB) and access
the CNS are unclear. In this study, we show that detection ofWNV by host tissues induces innate immune cytokine expression at
the BBB, regulating BBB structure and function and impacting transendothelial trafficking ofWNV. This regulatory effect is
shown to happen rapidly following exposure to virus, to occur independently of viral replication within BBB cells, and to require
the signaling of cytoskeletal regulatory Rho GTPases. These results provide new understanding of host-pathogen interactions at
the BBB during viral encephalitis.
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The central nervous system (CNS) is normally protected frompathogens by the blood-brain barrier (BBB), which is com-
posed of brainmicrovascular endothelial cells (BMECs) joined by
tight junctions (TJs). TJs are formed by the intercellular associa-
tion of transmembrane proteins, including claudins and occlu-
dins, whose anchoring to the endothelial cytoskeletal network by
adaptor proteins, including the zonula occludens family, repre-
sents amajor regulatorymechanismbywhich paracellular perme-
ability is controlled (1). Viruses may cross the BBB via several
routes, including direct infection of BMECs, trans- or paracellular
viral trafficking across the endothelium (2), or entry of infected
peripheral leukocytes (3, 4). Trafficking of virus across the BBB is
likely made possible by enhanced permeability of the BBB endo-
thelium, caused either directly by viral factors or indirectly by host
immune factors, including innate cytokines such as tumor necro-
sis factor alpha (TNF-) and interleukin-1 (IL-1) (5, 6). How-
ever, the mechanistic explanation of this effect and the functions
of innate immune responses at the BBB interface during viral in-
fections have not been explored.
West Nile virus (WNV), a mosquito-borne flavivirus, is the
most common cause of epidemic viral encephalitis in the United
States (7). Following infection, the pattern recognition receptors
(PRRs) TLR3, TLR7, RIG-I, and MDA5 are key sensors of WNV
pathogen-associated molecular patterns (PAMPs), inducing the
expression of innate Th1 cytokines that limit viral replication,
facilitate antigen presentation, and direct the trafficking of antivi-
ral leukocytes (8, 9). Studies with mice have shown that TNF-
signaling is key for CD8T cell-mediated clearance ofWNV from
the CNS (10), as well as protection from CXCR3-mediated apo-
ptosis in neurons (11). Likewise, IL-1 signaling has been shown
to limit WNV replication in neurons (12) and is essential for
dendritic-cell-mediated reactivation of WNV-specific T cells in
the CNS (13). Despite these beneficial effects in the CNS, Th1
cytokine signaling can also contribute to neuropathology, includ-
ing disruption of the BBB (6, 14).
PRR activation also induces the expression of type I interferons
(IFN- and IFN-) that share a type I IFN receptor (IFNAR).
PRR-mediated expression of IFN ligands results in the ampli-
fication of type I IFN signals via both autocrine and paracrine
signaling through IFNAR, which stimulates further IFN ligand
expression and an array of IFN-stimulated antiviral and immuno-
modulatory genes (15). Type I IFNs act directly as potent suppres-
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sors of viral replication (16) and indirectly by promoting host
adaptive immune responses (17). Thus, mice lacking type I IFN
receptors, ligands, and key transcription factors exhibit expanded
viral tropism and replication, resulting in accelerated and en-
hanced death (16, 18, 19). In the context of CNS autoimmunity,
type I IFNs can enhance BBB function and are used clinically in
humans to prevent the CNS entry of autoreactive leukocytes in
patientswithmultiple sclerosis (20, 21).However, the functions of
type I IFN at the BBB interface during viral infections of the CNS
have not yet been explored.
Here, we demonstrate a novel mechanism underlying the dy-
namic regulation of BBB structure and function by innate cyto-
kines during viral encephalitis. Using an in vitro BBB model, we
show that, in the presence of WNV, the induction of type I IFN
directly regulates endothelial permeability and TJ formation via
regulation of the small GTPases Rac1 and RhoA and indirectly via
suppression of barrier-dysregulating effects of TNF- and IL-1.
This regulatory regimen modulates transendothelial WNV traf-
ficking, as type I IFN responses significantly decreased the move-
ment of virus across an intact barrier in vitro, while TNF- and
IL-1 increased this crossing. In vivo, genetic attenuation of type I
IFN signaling resulted in enhanced BBB permeability with associ-
ated TJ disruption following peripheral or intracranial (i.c.) inoc-
ulation with WNV. Together, these data demonstrate an addi-
tional, previously undescribed, regulatory role for PRR-mediated
cytokine expression at the BBB during WNV infection.
RESULTS
Innate cytokines differentially regulate barrier function follow-
ing WNV infection. To assess the kinetics of BBB permeability
following murine WNV infection, we utilized an established
model of WNV neuroinvasive disease in which 5-week-old
C57BL/6 mice are subcutaneously infected in the footpad with
102 PFU of a virulent strain of WNV-NY. Five-week-old mice
uniformly develop CNS infection, with detectable CNS viral loads
first emerging ~6 days following infection (22, 23) (see Fig. S1A in
the supplemental material). Fluorometric assessment of BBB per-
meability following the intraperitoneal (i.p.) administration of
sodium fluorescein revealed that BBB permeability increased sig-
nificantly over the course of peripheral infection (days 0 to 4) in all
of the CNS regions analyzed (Fig. 1A). Of interest, BBB permea-
bility exhibited a significant decrease at day 6 in cortical and sub-
cortical cerebral tissues, coincident with the timing of detection of
virus within the CNS (see Fig. S1A). After this, BBB permeability
rebounded and returned to elevated levels on day 8, coinciding
with increased trafficking of leukocytes into the CNS (22).
The biphasic kinetics of BBB permeability afterWNV infection
suggested potentially differential regulation of the BBB by viral
and host factors over the course of infection. To assess this, we
utilized a standardTranswell in vitroBBB system inwhich primary
murine BMECs are grownon a porous filtermembrane in a cham-
ber suspended above primary murine astrocytes. The integrity of
the endothelial barrier is assessed via electrode recording of trans-
endothelial electrical resistance (TEER). We treated in vitro BBB
cultures in the top (BMEC-only) chamber overnight with cyto-
kines or infected them for 6 h at a multiplicity of infection (MOI)
of 0.01 with WNV that had been purified via ultracentrifugation
through a sucrose gradient. We utilized a low MOI for BMEC
experiments in light of the relatively low viremia present in mam-
malian hosts during WNV infection (24) and the fact that high
MOIs can trigger fast necrotic cell death (25), compromising
monolayer integrity and confounding the interpretation of TEER
results. Similarly, 6-h infections were chosen because this period
of time is insufficient for completion of the viral life cycle and
induction of apoptosis in BMECs, as assessed viamultistep growth
curves and terminal deoxynucleotidyltransferase-mediated
dUTP-biotin nick end labeling (TUNEL) staining (see Fig. S1B
and C in the supplemental material). Treatment with Th1 cyto-
kines TNF- (100 ng/ml), IL-1 (100 ng/ml), and IFN- (100 ng/
ml) decreased TEER, while IFN- (100 pg/ml) and WNV infec-
tion both significantly enhanced TEER (Fig. 1B). TEER effects
induced by Th1 cytokines could be rescued by subsequent infec-
tion with WNV, while infection of IFN--treated cultures pro-
duced no additional increase in TEER (Fig. 1B). Similar to WNV,
addition of IFN- to cultures pretreated with Th1 cytokines also
rescued TEER (Fig. 1C). These data suggest that WNV infection
may increase TEER either via type I IFN or through convergent
mechanisms.
To assess whether type I IFN expression by BMECs and/or
astrocytes contributes to increasing TEER, we performed check-
erboard experiments with BMECs and astrocytes isolated from
wild-type (WT) and/or Ifnar/mice. While TEER increased af-
ter 6 h of infection in cultures withWT BMECs, similarly infected
cultures generated with Ifnar/ BMECs instead exhibited signif-
icant reductions in TEER (Fig. 1D). While type I IFN signaling in
BMECs robustly controlled TEER responses after infection, type I
IFN signaling in astrocytes produced smaller but significant mod-
ulations of TEER responses as well. Experiments with neutralizing
antibodies to IFNAR and IFN ligands recapitulated the results
obtained with Ifnar/ BMECs (data not shown). Given the dra-
matic change in TEER responses in the absence of type I IFN
signaling, we next assessed the expression of innate cytokines in
BMECs following infection. In WT BBB cultures, the expression
of both IFN- and TNF- is induced within 6 h in the top cham-
bers of BBB cultures, with mostly undetectable levels of IL-1.
However, infection of Ifnar/ BBB cultures yielded lower levels
of type I IFNs (Fig. 1E; see Fig. S2A and B in the supplemental
material), consistent with a loss of IFNAR-mediated amplifica-
tion, as well as modestly enhanced TNF- and more robustly en-
hanced IL-1 expression (Fig. 1E). Baseline expression of cyto-
kines in uninfected cultures did not differ between genotypes (see
Fig. S2), and cytokine expression in bottom culture chambers did
not differ substantially from that in top culture chambers (data
not shown). These data indicate that type I IFN signaling in
BMECs can modulate permeability both directly and indirectly
through the suppression of Th1 cytokine expression.
To determine if permeability changes are associatedwith struc-
tural changes involving TJs, BMECmonolayers treated overnight
with cytokines, followed by 6 h ofWNV infection, were evaluated
by immunocytochemistry (ICC) for the TJ proteins Zo-1 and
Claudin-5. Infection of WT cells enhanced TJ protein colocaliza-
tion at intercellular borders, indicating the recruitment and stabi-
lization of these proteins in functional TJ complexes (Fig. 1F and
G). In contrast and consistent with TEER responses, infection of
Ifnar/ BMECs resulted in decreased TJ protein colocalization,
suggesting that type I IFN is necessary to enhance TJ formation in
the presence of WNV. Also mirroring our prior TEER results,
TNF- or IL-1 treatment resulted in decreased TJ protein colo-
calization, which could be rescued by subsequent WNV infection
in WT, but not Ifnar/, BMECs. These data indicate that innate
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cytokine signaling in BMECs following exposure to WNV results
in the rapidmodulation of TJ complexes, which are key regulators
of paracellular permeability, and that barrier dysregulation byTh1
cytokines can be controlled by the actions of type I IFN.
PRR activation is sufficient to induce cytokine-dependent
changes in endothelial barrier integrity. As type I IFN signaling
enhances both TJ formation and BBB permeability after WNV
infection,we assessedwhether thiswas the result of classical innate
immune signaling through PRRs. First, we inactivated purified
WNV via either 2 h of exposure to UV light (WNV-UV) or incu-
bation with 0.1% (vol/vol) -propiolactone (WNV-BPL), gener-
ating viral stocks that are unable to replicate within cells, as as-
sessed via standard plaque assay (data not shown), but do induce
the expression of both IFN- and IFN- in BMECs after 6 h (see
Fig. S2A and B). Treatment of in vitro BBB cultures consisting of
WTversus Ifnar/BMECs (both overWTastrocytes) with either
WNV-UV or WNV-BPL at an MOI of 0.01 (Fig. 2A) for 6 h re-
vealed enhanced TEER in WT cultures but reduced TEER in If-
nar/ cultures, largely phenocopying the effect of normal virus.
These results suggest that type I IFN-dependent changes in TEER
require viral detection but not replication in BMECs.
We next determined if direct activation of PRRs was sufficient
to alter TEER. TLR3 agonism via 6 h of treatment with naked
(nontransfected) poly(I · C) at 1 g/ml significantly decreased
FIG 1 WNV infection modulates endothelial barrier integrity via innate cytokine signaling. (A) Five-week-old C57BL/6 mice were inoculated in the footpad
with 100 PFU of WNV and then assessed for BBB sodium fluorescein permeability in CNS regions on the postinfection days indicated. The values reported are
arbitrary fluorescence values in CNS tissue normalized to values in serum for individual mice. Group means are normalized to the mean value for uninfected
animals. The values on the x axes are times in days. n.s., not significant. (B) In vitroBBBswere treated overnight in the top chamberwith the saline vehicle, TNF-,
IFN-, IL-1, or IFN-, followed by an additional 6 h of infection withWNV and subsequent measurement of TEER. (C) BBB cultures were treated for 2 h with
the vehicle or the cytokine indicated, and then the culturemediumwas washed away and replaced withmedium containing the vehicle or IFN- for 2 h, followed
bymeasurement of TEER. (D) In vitro BBBs were constructed withWT or Ifnar/ BMECs cocultured with astrocytes of either genotype, as shown on the x axis,
with the BMEC genotype on the left and the astrocyte genotype on the right. TEERmeasurements after 6 h of WNV infection are shown. (E) ELISA of cytokine
expression in the top chambers of BBB cultures following 6 h of WNV infection. (F) Quantification of ICC analysis of colocalization of Zo-1 and Claudin-5 in
WT and Ifnar/ BMECmonolayers treated for 2 h with the saline vehicle or the cytokine indicated and subsequently infected for 6 h with WNV at an MOI of
0.01. Values on the y axis (correlation indexes) represent the probability of an individual pixel staining positive for bothmarkers if it stains positive for either. (G)
Representative63 images of cultures with Zo-1 shown in green, Claudin-5 in red, and Topro3 nuclear staining in blue. Scale bar 25 m.White arrowheads
highlight junctions with loss of TJ protein colocalization. Veh, vehicle.
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TEER in bothWT and Ifnar/ BBB cultures (Fig. 2A). However,
similar 6-h treatments with agonists for TLR7 (CL264, 10g/ml),
MDA5 [high-molecular-weight poly(I · C), 1 g/ml, transfected
into cytoplasm], or RIG-I (5= triphosphate double-stranded RNA
[ppp-dsRNA], 1 g/ml, transfected into cytoplasm) instead re-
sulted in increased TEER in WT cultures but decreased TEER in
Ifnar/ cultures, similar to the results obtained with both infec-
tious and inactivated WNV. Enzyme-linked immunosorbent as-
say (ELISA) results confirmed that the expression of both IFN-
and IFN- was induced by all of the treatments used, including a
TLR3 agonist (see Fig. S2A and B). Consistent with these results,
ICC analysis of Zo-1 and Claudin-5 similarly showed enhanced
colocalization in WT BMECs treated for 6 h with WNV-UV,
WNV-BPL, andTLR7,MDA5, andRIG-I, but not TLR3, agonists,
with decreases in TJ protein colocalization after these treatments
in Ifnar/ BMECs (Fig. 2A and B). TLR3 agonism, however,
resulted in decreases in TJ protein colocalization in both WT and
Ifnar/ cultures.
We next assessed if differences in barrier responses to PRR
agonists in WT versus Ifnar/ BBB cultures and between TLR3
and other PRR agonists were due to differential cytokine expres-
sion. Similar to experiments with WNV, Ifnar/ BBB cultures
had small modulations of type I IFN and TNF- signaling after
stimulation with inactivated virus and PRR agonists (see Fig. S2A
FIG 2 PRR activation is sufficient to induce cytokine-dependent changes in endothelial barrier integrity. (A, left side) TEER measurements for in vitro BBBs
constructed with either WT or Ifnar/ BMECs over WT astrocytes, treated for 6 h at an MOI of 0.01 with WNV inactivated with UV (WNV-UV),
-propiolactone (WNV-BPL), the TLR3 agonist “naked” poly(I · C), the TLR7 agonist CL264, theMDA5-biased agonist HMWpoly(I · C)-LyoVec, or the RIG-I
agonist 5= ppp-dsRNA. (A, right side) Quantification of ICC analysis of colocalization of Zo-1 and Claudin-5 inWT versus Ifnar/ BMECs treated as indicated
on the left. Values on the x axis (correlation indexes) represent the probability of an individual pixel staining positive for both markers if it stains positive for
either. (B) Representative63 images showing colocalization of Zo-1 and Claudin-5 in WT versus Ifnar/ BMECmonolayers treated for 6 h with inactivated
WNV or a PRR agonist (as in panel A), with Zo-1 shown in green, Claudin-5 in red, and Topro3 nuclear staining in blue. White arrowheads highlight junctions
with loss of TJ protein colocalization. (C) ELISA of cytokine production in the top chambers of BBB cultures as in panel A following 6 h of treatment with either
“naked” poly(I · C) or CL264. (D) BBB cultures as in panel A were pretreated with neutralizing antibodies to TNF- and/or IL-1 or isotype controls. Cultures
were then infected for 6 h with WNV at an MOI of 0.01 (left panel) or treated for 6 h with “naked” poly(I · C) or CL264 (middle and right panels). Data are
expressed as fold changes in infected/treated cultures versus similarly treated mock-infected/vehicle-treated cultures under the same conditions.
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to C) and, strikingly, significantly enhanced expression of IL-1
compared to that in WT cultures (see Fig. S2D). Moreover, TLR3
agonism resulted in IL-1 expression even in WT cultures
(Fig. 2C), in contrast to cultures treated with other PRR agonists,
including the TLR7 agonist CL264, which induced detectable lev-
els of IL-1 only in Ifnar/ BBB cultures (Fig. 2C; see Fig. S2D).
To determine if differential expression of Th1 cytokines contrib-
uted to differences in TEER responses in BBB cultures exposed to
WNV or PRR agonists for 6 h, wemeasured TEER in the presence
of cytokine-neutralizing antibodies. Blockade of TNF- aug-
mented increases in TEER in WT cultures following exposure to
WNV or a TLR7 agonist (Fig. 2D) and partially rescued decreases
in TEER in Ifnar/ cultures. In contrast, blockade of IL-1 did
not impact TEER inWNVandTLR7 agonist-treatedWT cultures,
which do not express IL-1 within 6 h, but did partially rescue
decreases in TEER in Ifnar/ cultures, which do exhibit IL-1
expression. Similarly, blockade of either TNF- or IL-1 partially
rescuedTEER responses inTLR3 agonist-treated cultures of either
genotype (Fig. 2D). Of note, simultaneous blockade of both
TNF- and IL-1 in Ifnar/ cultures following exposure to
WNV or PRR agonists held TEER levels at baseline values. To-
gether, these data suggest that innate cytokine signaling in BMECs
orchestrates barrier responses following exposure to WNV
PAMPs and that the relative balance of type I IFN versus TNF-
and IL-1 governs these changes. Type I IFN signaling in BMECs
is able to prevent BBB dysregulation by Th1 cytokines, which, in
the absence of type I IFN, are able to increase barrier permeability
and disassemble TJs.Moreover, PRR activation in BMECs, even in
the absence of direct infection, is sufficient to induce cytokine-
mediated changes in BBB physiology.
WNV modulates BMEC Rho GTPase signaling in an innate
cytokine-dependent manner. To assess the signaling events that
regulate BBB physiology downstream of WNV and cytokine sig-
naling, we examined if WNV infection resulted in changes in the
activity of Rho GTPases, a family of signaling molecules that reg-
ulate cytoskeletal dynamics, including TJs and paracellular per-
meability (26).WT and Ifnar/BMECmonolayers were infected
for 6 h with WNV, and protein lysates were collected and incu-
bated with Rhotekin or p21-activated protein kinase (PAK) aga-
rose beads to pull down GTP-bound, activated Rac1, RhoA, and
CDC42. Western blot detection of activated forms of these GT-
Pases revealed a significant increase in activated Rac1 in WNV-
infected WT BMECs (Fig. 3A and B) and a significantly smaller
increase in activated Rac1 in Ifnar/ BMECs. In contrast, while
activated RhoA was not increased in WNV-infected WT BMECs,
Ifnar/ BMECs exhibited significantly increased amounts of ac-
tivated RhoA (Fig. 3A and C). Levels of activated CDC42 were not
affected by WNV infection in either WT or Ifnar/ BMEC cul-
tures (Fig. 3A and D). As these experiments suggested a dynamic
range of Rho GTPase activation responses following WNV infec-
tion, we next assessed the manner in which individual innate cy-
tokines regulate Rho GTPase activation. In agreement with infec-
tion experiments with WT versus Ifnar/ BMECs, 2 h of
incubation of WT BMECs with recombinant IFN- resulted in
significantly enhanced Rac1 activation (Fig. 3E and F) and signif-
icantly diminished RhoA activation (Fig. 3E and G). In contrast, 2
h of incubation with TNF- resulted in decreased Rac1 activation
and greater activation of RhoA, while 2 h of IL-1 treatment in-
creased the activation of both GTPases, with a greater fold change
in induction of RhoA activation.
Innate cytokine-dependent modulation of Rac1 and RhoA
afterWNV infection regulates BBB permeability and TJ forma-
tion. We next examined whether modulation of BMEC Rho GT-
Pase signaling in the context ofWNV infection contributes to type
I IFN-dependent regulation of TEER and TJ responses. Pharma-
cological blockade of Rac1 signaling via 2 h of pretreatment with
its specific inhibitor, Z62954982, abolished the increase in TEER
after 6 h of WNV infection in WT cells, with TEER values signif-
icantly decreased in WNV-infected WT barriers in the absence of
Rac1 signaling, while responses remain unchanged in similarly
infected and treated Ifnar/ barriers (Fig. 3H). Conversely, inhi-
bition of RhoA signaling via 2 h of pretreatment with its specific
inhibitor, H1152P, did not impact TEER changes induced by
WNV infection in WT barriers but significantly rescued reduc-
tions in TEER in similarly infected and treated Ifnar/ barriers.
Inhibition of CDC42 via 2 h of pretreatment with ML141, a spe-
cific inhibitor of CDC42, did not significantly alter TEER in either
WTor Ifnar/ barriers afterWNV infection. As changes in TEER
responses could simply be explained by altered IFN expression by
BMECs following infection in the presence of GTPase inhibitors,
we confirmed via ELISA that inhibition of Rac1 or RhoA did not
significantly alter IFN- levels in luminal chambers following 6 h
of infection and that none of the inhibitors impacted TEER in
cultures mock infected for 6 h (see Fig. S3A to C in the supple-
mental material).
Consistent with analyses of TEER, ICC analysis further re-
vealed that inhibition of Rac1 signaling in WT cells completely
abolished the increase in the colocalization of Zo-1 and Claudin-5
observed in WNV-infected WT BMECs (Fig. 3I and J), while in-
hibition of RhoA or CDC42 did not impact TJ formation in WT
cells. However, inhibition of RhoA rescues the loss of TJ forma-
tion inWNV-infected Ifnar/BMECs, abolishing decreases inTJ
protein colocalization observed in untreated Ifnar/BMECs. In-
hibition of Rac1 or CDC42 did not significantly impact TJ forma-
tion in Ifnar/BMECs. Control experiments also confirmed that
2 h of pretreatment with GTPase inhibitors, followed by 6 h of
mock infection, did not change baseline levels of TJ protein colo-
calization (see Fig. S3D). Together, these data suggest that cyto-
kines expressed in BMECs following exposure to WNV differen-
tially influence Rho GTPase activity, with type I IFN contributing
to the preferential activation of Rac1, thereby stabilizing barrier
physiology. This regulation counteracts the activity of the cyto-
kines TNF- and IL-1, which preferentially activate RhoA and
contribute to barrier disruption.
Innate cytokine regulation ofRhoGTPase signaling controls
WNV transmigration across the in vitro BBB. We next deter-
mined if cytokine and Rho GTPase modulation of TEER and TJ
integrity are relevant regulators of viral trafficking across the BBB,
limiting the access of WNV to the CNS. For these experiments,
WNV at an MOI of 0.01 was added to the top chamber of Trans-
well BBB cultures; 6 h later, the top chamber was removed, such
that only virus that had crossed during the 6 h of incubation was
present in the bottom chamber. Amounts of migrated virus in the
bottom chambers were then assessed via multistep growth curve
analysis. Consistent with changes in TEER and TJ integrity, over-
night pretreatment of the top chamber with TNF- or IL-1 be-
fore infection significantly enhanced the transendothelial migra-
tion ofWNV (Fig. 4A and B), while IFN- pretreatment of the top
chamber significantly reduced viral trafficking (Fig. 4C). Simi-
larly, experiments with barriers with WT versus Ifnar/ BMECs
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over WT astrocytes revealed that Ifnar/ BMECs exhibit signif-
icantly enhanced viral migration (Fig. 4D). In order to control for
the possibility that IFN- treatment or genetic deletion of IFNAR
onBMECs alters the basolateral secretion of type I IFNbyBMECs,
whichmay skew the kinetics of replication in the astrocytes below,
we did concurrent experiments with BBB cultures with Ifnar/
astrocytes. These experiments yielded similar results, confirming
that differential exposure of astrocytes to IFN did not account for
the difference observed in experiments with WT astrocytes (see
Fig. S4A and B in the supplemental material). Pretreatment of
BBB cultures with neutralizing antibodies to TNF- reduced viral
migration in bothWT Ifnar/ cultures, while pretreatment with
neutralizing antibodies to IL-1 reduced migration only in If-
nar/ cultures, consistent with similar experiments measuring
TEER responses (Fig. 4E andF).Once again, neutralizing antibod-
ies to both cytokines had additive effects on Ifnar/ barriers,
suppressing viral migration back to the levels observed in WT
cultures.
As cytokine signaling was observed to influence transendothe-
lial viral migration, we next performed similar experiments in
which cultures consisting of WT or Ifnar/ BMECs over WT
astrocytes were pretreated for 2 h in the top chamber with antag-
onists of Rac1, RhoA, or CDC42 prior to the introduction of
WNV. Again, consistent with TEER and TJ integrity findings, an-
tagonism of Rac1 significantly enhanced the transendothelial mi-
gration of WNV across WT BMECs but did not further augment
the enhanced migration observed across Ifnar/ BMECs
(Fig. 4G). Likewise, antagonismof RhoAdid not significantly alter
FIG 3 WNVmodulates endothelial Rho GTPase-mediated regulation of the BBB endothelium. (A to G) Activated GTPase pulldown assay of WT or Ifnar/
BMECs either infectedwithWNVat anMOI of 0.01 for 6 h (A toD) or treated for 2 hwith recombinant TNF-, IL-1, or IFN- (E toG). After treatment, BMEC
lysates were incubated with Rhotekin or PAK agarose beads to purify GTP-bound, activated Rac1, RhoA, and CDC42. Both purified activated GTPases and total
unpurified cell lysates were then probed via Western blot assay to assess activated versus total amounts of each GTPase. UI, uninfected. (B to D, F, G) Density
quantification of activated Rac1 (B, F), RhoA (C, G), or CDC42 (D), normalized to the total amount of each protein in each sample. Group averages are
normalized to the mean values of uninfected/vehicle-treated WT BMECs. (H) TEER measurements for in vitro BBBs constructed with WT or Ifnar/ BMECs
overWT astrocytes, pretreated for 2 hwith Rac1 inhibitor Z62954982, ROCK/RhoA inhibitorH1152P, or CDC42 inhibitorML141 and then infected for 6 hwith
WNVat anMOIof 0.01.Data are reported as fold changes inTEER in infected cultures versus uninfected cultureswithin each treatment group. (I) Representative
63 images showing colocalization of Zo-1 and Claudin-5 in WT versus Ifnar/ BMEC monolayers treated for 2 h with GTPase inhibitors (as in panel H),
followed by 6 h of infection with WNV at an MOI of 0.01, with Zo-1 shown in green, Claudin-5 in red, and Topro3 nuclear staining in blue. White arrowheads
highlight junctions with loss of TJ protein colocalization. (J) Quantification of colocalization in images in panel I. Data are reported as the fold changes in
colocalization in infected cells versus uninfected cells within each treatment group.
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WNVmigration acrossWTBMECs but resulted in a partial rescue
of the enhancedmigration observed in Ifnar/BMECs (Fig. 4H).
As expected antagonism of CDC42 did not impact the transendo-
thelial migration of WNV (see Fig. S4C). Together, these findings
suggest that modulation of BMEC TEER and TJs caused by type I
IFN-dependent regulation of RhoGTPases is consequential to the
ability of WNV to traffic across the BBB endothelium.
Mice with impaired type I IFN responses exhibit enhanced
BBB permeability and loss of TJ integrity after peripheralWNV
infection.Mice lacking a type I IFN receptor, ligands, and regula-
tory transcription factors exhibit enhanced susceptibility toWNV
infection, including early entry of virus into the CNS compared to
WT controls. Thus, in light of our in vitro observations, we won-
dered if mice with impaired type I IFN signaling would also ex-
hibit alterations in BBB permeability and TJ integrity following
peripheral infection. To determine whether type I IFN signaling is
required for the in vivo decrease in BBB permeability observed on
day 6 after WNV infection of the CNS, we examined BBB perme-
ability in the context of i.c. inoculation (10 PFU) of WNV in
8-week-old WT versus Ifnar/mice. WT animals experienced a
significant decrease in BBB permeability to sodium fluorescein on
days 1 and 2 in each CNS region, followed by a large increase in
BBBpermeability on day 4 (Fig. 5A), coincidentwith the detection
of large numbers of inflammatory cells at this time point in this
model (27).However, these kineticswere not observed in Ifnar/
animals, which instead exhibited a significant and sustained in-
FIG 4 Innate cytokines differentially regulate WNV transmigration across the in vitro BBB. (A to H) Detection of replicating virus in the bottom chambers of
in vitro BBBs constructed with the WT BMECs only (A to C) or WT or Ifnar/ BMECs (D to H) over WT astrocytes, infected with WNV at an MOI of 0.01 in
the top chambers for 6 h before removal of the top chambers. The cultures in panels A to C were treated overnight with the saline vehicle or TNF- (A), IL-1
(B), or IFN- (C) prior to infection. The cultures in panels E and Fwere pretreated for 2 hwith neutralizing antibodies toTNF- (E) or IL-1 (F) before infection.
The cultures in panels G andHwere pretreated for 2 hwith Rac1 inhibitor Z62954982 (G) or ROCK inhibitorH1152P (H) before infection. Values are viral titers
present after 0, 12, 24, and 48 h of replication by virus that crossed during the 6 h of infection, prior to the removal of BMECs from the culture system. Viral titers
are reported in plaque-forming units per milliliter, as determined via standard plaque assay in BHK cells. Each horizontal dotted line represents the limit of
detection of the assay.
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FIG 5 WTmice but notmice with impaired type I IFN signaling exhibit increased BBB integrity following neuroinvasion. (A) Eight-week-oldWT and Ifnar/
micewere i.c. inoculatedwith 10 PFUWNV.On the days indicated after infection,micewere administered sodiumfluorescein and then sodiumfluorescein levels
in tissue homogenates taken from CNS regions contralateral to the inoculation site were assessed. The values reported are arbitrary tissue fluorescence values
normalized to the serum values of individual mice. Group means are normalized to the mean value of mock-infected WT animals. (B) Sodium fluorescein
permeability in CNS regions after footpad inoculation with 100 PFUWNV. Values taken from CNS regions (both hemispheres) are reported as in panel A, with
normalization to values of uninfectedWTmice. (C) IHCdetection of serum IgG in parenchymalCNS tissues after peripheralWNV infection, with quantification
of group mean fluorescence intensity per low-power field. Scale bar 100 m. (D) IHC detection of Zo-1 (green) and Claudin-5 (red) in CNSmicrovessels on
the days after footpad infection indicated. Scale bar 10 m. (E) Eight-week-old WT and Ifnar/mice were administered 50 g poly(I · C) i.p., followed by
sodium fluorescein 24 h later (processed as described for panel B).
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crease in permeability to sodium fluorescein each day following
infection. For these studies, we examined permeability in tissues
contralateral to the inoculation site, though we ultimately found
that permeability did not differ significantly between hemispheres
on any day following i.c. infection (data not shown). Concurrent
experiments with mice that received mock i.c. inoculations with
saline showed only extremelymodest increases in BBB permeabil-
ity, which did not differ between WT and Ifnar/ mice (see
Fig. S5 in the supplemental material); thus, the inoculation pro-
cedure alone did not explain changes in BBB permeability follow-
ing i.c. inoculation with WNV. In all, these data suggest that local
type I IFN responses in the CNS following WNV entry promote
BBB integrity, which may contribute to the decrease in BBB per-
meability observed between days 4 and 6 following peripheral in-
fection.
As Ifnar/mice rapidly and uniformly die of septic shock (at
about 3.5 days after footpad infection) (16, 28), we next used
Irf7/ mice, which have impaired expression of IFN- (29).
These mice experience early neuroinvasion of WNV compared to
WT mice following footpad infection (29). Sodium fluorescein
permeability experiments revealed that WNV-infected 8-week-
old WT mice exhibit BBB permeability kinetics similar to those
previously observed in 5-week-old animals, including an increase
in permeability during peripheral infection (days 0 to 4), followed
by a decrease in permeability at day 6 (Fig. 5B). In contrast,WNV-
infected 8-week-old Irf7/ mice exhibit a sustained increase in
BBB permeability over the entire course of infection, with signif-
icantly higher permeability than that of WT controls on day 6.
Immunohistochemical (IHC) detection of extravasated endoge-
nous IgG revealed similar kinetics of permeability followingWNV
infection in cortical and cerebellar tissues (Fig. 5C). Consistent
with this, IHC detection of Zo-1 and Claudin-5 in CNS tissues
revealed that both WT and Irf7/ mice exhibited loss of TJ in-
tegrity on day 4 following WNV infection, characterized by di-
minished or diffuse cytoplasmic staining of TJ proteins and sub-
stantially decreased colocalization of TJ proteins at cell-cell
borders (Fig. 5D). Alteration in TJ assembly was reversed at day 6
within the microvasculature of WNV-infected WT mice, while
that of similarly infected Irf7/mice showed sustained dysregu-
lation of TJs. As differences between the viral burdens of WT and
Irf7/ mice over time complicate the interpretation of BBB
changes due to type I IFN signaling, we performed control exper-
iments in which WT and Ifnar/ mice were treated with the
TLR3 agonist poly(I · C), which is known to increase BBB perme-
ability (6). At 24 h following treatment, Ifnar/ mice exhibited
greater CNS permeability to sodium fluorescein than WT mice
(Fig. 5E), providing further evidence that type I IFN signaling is
required to preserve BBB integrity in the context of systemic in-
flammatory activation.
DISCUSSION
While the contributions of innate cytokine responses to virologic
control and adaptive immunity during WNV infection are
known, the regulatory potential of these molecules at the BBB
remains poorly understood. Here, we demonstrate that PRR acti-
vation in the presence of WNV in the BBB endothelium results in
cytokine-dependent modulation of Rho GTPase signaling, exert-
ing regulatory control over BBB permeability and TJ integrity.
This, in turn, is consequential for the ability of WNV to traffic
across the BBB endothelium. In particular, our data suggest that
the induction of type I IFN serves to preserve and stabilize BBB
structure and function both directly and indirectly by limiting
barrier disruption caused by the cytokines TNF- and IL-1. In
vivo, BBB permeability increases during peripheral infection but
sharply decreases coincident with viral neuroinvasion in WT an-
imals but not in animals with attenuated type I IFN responses,
suggesting that local CNS type I IFN responsesmay act on the BBB
to mitigate the access of WNV to the CNS parenchyma.
The Th1 cytokines TNF- and IL-1 have previously been
shown to disrupt barrier endothelium in vitro and in vivo, increas-
ing permeability (30–32) and dysregulating junction complexes
(1, 33, 34). During viral infections, TNF-, in particular, has been
linked to enhanced vascular permeability, poor tissue perfusion,
and endothelial cell death (28, 35). Here, we show that TNF-
signaling in BMECs activates RhoA, disrupting barrier function
and increasing the transendothelial movement ofWNV. This is in
line with the study of Wang et al. (6), who reported a decrease in
BBB permeability in Tnfrsf1a/mice following WNV infection.
These findings together indicate that Th1 cytokine-mediated dis-
ruption of the BBB provides an access route for neuroinvasion by
WNV.
In contrast to Th1 cytokines, type I IFN treatment has been
established to promote BBB function (34, 36). However, for the
first time, we demonstrate that in vivo induction of type I IFN
following WNV infection is a key regulator of BBB permeability
and TJ integrity. Type I IFN signaling in BMECs in vitro is shown
to enhance barrier function over baseline conditions and to rescue
Th1 cytokine-mediated barrier dysregulation, suggesting that
CNS type I IFN responses may be able to reverse the BBB perme-
ability caused by Th1 cytokine production during infection in
vivo. This interpretation agrees with in vitro observations suggest-
ing that dengue virus activation of type I IFNs reduces vascular
leakage in peripheral endothelium, even in the presence of the
barrier-disrupting cytokines (35). Type I IFN also preserves bar-
rier integrity by suppression of Th1 cytokine expression, most
noticeably, that of IL-1. While the interactions of type I IFN and
IL-1 during WNV infection vary across tissues and times after
infection (12, 13), type I IFN has been shown to suppress IL-1
expression via mechanisms that vary by cell type and inflamma-
tory stimulus, including inhibition of inflammasome activity and
pro-IL-1 and pro-IL-1 expression (37, 38). To our knowledge,
we are the first to demonstrate IFN-mediated suppression of en-
dogenous IL-1 in the BBB endothelium. While this report and
others have identified a role for IL-1 signaling in BBB breakdown
(39, 40), we note our previous study showing that IL-1 signaling at
the BBB is an important facilitator of lymphocyte activation and
trafficking into the CNS during WNV infection and was crucial
for viral clearance and survival (13). Moreover, Ramos et al. (12)
found that type I IFNs and IL-1worked synergistically to control
WNV in neurons. Thus, IL-1 signaling during WNV infection
may serve both pathological and protective functions, and the
modulation of these effects by type I IFN likely varies over time
and by cell type.
Some studies of murine WNV encephalitis have reported a
sustained increase in BBB permeability over the course of infec-
tion, with permeability rising coincident with neuroinvasion and
continuing to increase thereafter (41, 42). However, our findings
more closely resemble those showing markedly enhanced BBB
permeability 3 to 4 days postinfection, prior to neuroinvasion (6,
43, 44). Wang et al. (6) additionally observed reduced BBB per-
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meability on day 5 postinfection, coincident with neuroinvasion,
in concordance with our findings. A similar biphasic response in
BBB permeability was also observed in a model of Venezuelan
equine encephalitis virus infection (45). The reasons for these dis-
crepancies are unclear and may include variations in the viral in-
oculation site and the age of the experimental animals used. Nev-
ertheless, our data suggest that type I IFN suppresses BBB
permeability during viral infection, as loss of intact type I IFN
signaling enhanced BBB permeability following both peripheral
and CNS WNV inoculations. While tissue viral burden and im-
mune activation differences between Ifnar/ and Irf7/ mice
after peripheral infection may independently contribute to the
observed differences in BBB permeability, we note that, following
i.c. inoculation, BBB permeability was demonstrated to be signif-
icantly higher in Ifnar/ animals, even 1 day after infection when
CNS viral titers have been shown to be equivalent (16).
Cytokine-mediated regulation of the BBB is likely to arise from
many diverse sources, including peripheral/serum cytokines, CNS
cytokines produced by resident and infiltrating cells, as well as
cytokines produced by the BBB endothelium that signal in an
autocrine or paracrine fashion among BMECs. Here, we have fo-
cused our investigation specifically on BMEC-intrinsic cytokine
signals, though our data and previous studies provide some clues
as to how cytokine signaling from each of these sources may or-
chestrate the observed changes in BBB permeability. In vivo BBB
permeability seems to peak initially at day 4 postinfection, most
likely because of the actions of Th1 cytokines that accumulate in
serum during peripheral infection (13, 46). After viral neuroinva-
sion, type I IFN is rapidly produced in the CNS, appearing as early
as day 5 postinfection (16), while Th1 cytokines are generally not
expressed in significant amounts until day 7 or 8 (12, 13, 47).
Thus, the initial interaction of the viruswith the BBB endothelium
and early IFN production within the infected CNS on days 5 and 6
likely function together to produce a decrease in BBB permeabil-
ity. Increases in inflammatory cytokine levels during later stages of
CNS infection derive from both innate immune responses of CNS
cells and infiltrating leukocytes expressing TNF- and IFN-,
which also are first detectable in significant quantities 7 to 8 days
postinfection (47–49). Likewise, following i.c. inoculation, type I
IFNs are induced within 2 days (29) as BBB permeability de-
creases, followed by the infiltration of inflammatory cells on day 4
(27) and a subsequent increase in BBB permeability. Ultimately,
the exact timing of the expression and interaction of IFNs and
inflammatory cytokines expressed in various compartments fol-
lowing WNV infection is complex and, as in studies of BBB per-
meability, sometimes differ among reports. However, on the basis
of our findings and the general trends observed in the literature, it
appears that systemic immune factors contribute to BBB break-
down during peripheral infection, whichmay contribute toWNV
entry into theCNS.Around the time ofCNSneuroinvasion, direct
interaction of the virus with the BBB endothelium and early, local
innate immune responses in the CNS lead to a type I IFN-
dependent decrease in BBB permeability, which may be reversed
by infiltration of the CNS by inflammatory cells.
Cytokine-mediated BBB regulation is shown to occur via PRR
pathways, independently of viral replication, as detection of viral
PAMPs inBMECswas sufficient for the regulation of barrier phys-
iology. In particular, agonism of WNV-sensing PRRs RIG-I,
MDA-5, andTLR7 induced cytokine responses dominated by type
I IFN, thereby enhancing barrier function. Prior studies have re-
vealed that deficiencies in each of these pathways result in in-
creased disease susceptibility, including early neuroinvasion and
greater CNS viral burdens during WNV infection (27, 50, 51). Of
note, unlike other PRRs, TLR3 agonism increased barrier dys-
regulation in both WT and Ifnar/ BMECs. Compared to other
PRRs, TLR3 induced cytokine responses more heavily skewed to-
ward Th1 cytokines and, uniquely, stimulated rapid expression of
IL-1, even in WT cells. These data align with a previous report
(6) suggesting that TLR3 activation contributed to BBB break-
down and subsequent WNV neuroinvasion. In our study, in vivo
TLR3 agonism also induced BBB permeability and did so more
efficiently in Ifnar/ than WT mice, again suggesting that type I
IFN expression may counterregulate the effects of TNF- and
IL-1 at the BBB. The specific role of TLR3 duringWNV enceph-
alitis remains uncertain, as another report (3) was unable to link
TLR3 activation to BBB breakdown. Ultimately, TLR3 signals
through an adaptor different from that used by other PRRs (52)
and thusmay exhibit different regulatory properties at the BBB, as
has been shown in other tissues (53). As demonstrated by Verma
et al. (2), we found that WNV is capable of trafficking across the
BBB endothelium in vitro, though this study used highMOIs over
several days, leading to increased virus in bottom chambers be-
cause of replication within endothelium, independently of para-
cellular permeability. Alternatively, we show that the virus can
cross the BBB endothelium quickly after exposure, independently
of replication, and that trafficking is correlated with paracellular
permeability. Movement of virus in this manner is likely relevant
in vivo, as studies have linked host factors that contribute to BBB
disruption to WNV neuroinvasion (44, 54, 55). We also demon-
strate a rapid (6 h), cytokine-dependent regulation of TJ protein
localization after infection. Type I IFN regulation of BMEC TJs
was due to the activation of Rac1 and suppression of RhoA activ-
ity, a regulatory regimen well known to control TJ integrity (26).
This finding is in line with a report demonstrating that RhoA
contributed to the dysregulation of BMECTJs, enhancing the traf-
ficking of HIV-1-infected monocytes across the BBB (56). Thus,
regulation of this pathway may serve to limit CNS trafficking of
both free and cell-associated WNV.
Understanding how viral and host factors contribute to the
development of neuroinvasive disease is a critical step in develop-
ing treatment and prevention strategies for WNV encephalitis.
IFN therapy has been used with some success in immunocompe-
tent patientswithWNVencephalitis (57, 58), while IFN therapy in
immunosuppressed patients, such as recipients of infected trans-
plant organs, has been less successful, according to case reports
(59). A limitation of the human treatment literature, however, is
that patients have typically developed neuroinvasive disease be-
fore treatment; this caveat, combined with the broad systemic
effects of IFN therapy, limits our understanding of how IFN may
regulate BBB function in human patients. A more promising line
of investigation includes the identification of genetic differences
in innate immune pathways that may influence disease suscepti-
bility to encephalitis-causing viruses. Studies thus far have associ-
ated polymorphisms in several type I IFN pathway elements, in-
cluding IRF3,MX1, andOAS1, with susceptibility to symptomatic
WNV infection (60, 61). In addition, enhanced TLR3 activity and
inflammatory cytokine production after WNV infection have
been shown in macrophages obtained from elderly patients com-
pared to those of young controls, which may contribute to the
enhanced susceptibility of older individuals to neuroinvasive dis-
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ease (62). Thus, understanding how variations in innate immune
factors contribute to susceptibility to viral encephalitis may in-
form new strategies for prevention and targeted therapeutics.
MATERIALS AND METHODS
Murine model of WNV encephalitis. Five- and 8-week-old C57BL/6
mice were commercially obtained (Jackson Laboratories). Congenic If-
nar/ and Irf7/ mice were the generous gift of Michael Diamond
(Washington University in St. Louis). All animals were housed under
pathogen-free conditions in the animal facilities of the Washington Uni-
versity School of Medicine. All experiments were performed in compli-
ance with Washington University animal studies guidelines. Mice were
inoculated subcutaneously via footpad injection (50l) or i.c. (2l) with
either 100 or 10 PFU of WNV, respectively, as previously described (23).
WNV strain 3000.0259 (isolated inNewYork in 2000 [63]) was used in all
experiments. Viral titers in all experiments were determined via standard
plaque assay in BHK21-15 cells as previously described (64).
In vivo assessment of BBBpermeability.At various day intervals after
infection, mice were injected i.p. with 100 l of 100 mg/ml fluorescein
sodium salt (Sigma-Aldrich) in sterile phosphate-buffered saline (PBS).
After 45 min, mice underwent extensive cardiac perfusion with PBS, fol-
lowed by collection of blood and harvesting of CNS tissues. Tissue ho-
mogenates and serumwere incubated overnight at 4°C at a 1:1 dilution in
2% trichloroacetic acid (Sigma-Aldrich) to precipitate protein, which was
pelleted by 10 min of centrifugation at 4,000 rpm at 4ºC. Supernatants
were then diluted in equal volumes of borate buffer, pH 11 (Sigma-
Aldrich). Fluorescence emission at 538 nm was determined via a Synergy
H1microplate reader and Gen5 software (BioTek Instruments, Inc.). Tis-
sue fluorescence values were standardized against plasma values for indi-
vidual mice.
In vitroBBB cultures and TEER recordings. Primarymurine BMECs
were prepared from 8- to 10-week-old WT and Ifnar/ mice as previ-
ously described (65). Primary neonatal murine astrocytes were prepared
from WT and Ifnar/ pups (postnatal days 1 to 3) from mixed glial
cultures as previously described (66). In vitro BBB cultures were then
prepared as previously described (67). Briefly, 105 BMECs were cultured
on the apical side of a 0.9-cm2 fibronectin-coated polyethylene terephtha-
late filter insert with a 3.0-m pore size (BD Falcon). A total of 105 astro-
cytes were cultured concurrently in 12-well plates until they reached con-
fluence (~2 days), at which point BMEC inserts were added to astrocyte
cultures. Resistance recordings weremade via chopstick electrode with an
EVOM voltmeter (World Precision Instruments). Resistance values are
reported in/cm2 (recorded values minus values for cell-free inserts).
ICC and IHC analyses. ICC analysis on primary BMECs was per-
formed after 10min of fixation in ice-coldmethanol, followed by blocking
for 30 min in 10% goat serum in PBS at room temperature (RT). Cells
were then incubated with primary antibodies to Zo-1 (rat anti-mouse
monoclonal antibody, clone R40.76; Millipore) and Claudin-5 (rabbit
anti-mouse polyclonal antibody; Invitrogen) in blocking buffer for 1 h at
RT, washed three times in PBS, and then incubated for 15 min in goat
anti-rat Alexa Fluor 488-conjugated and goat anti-rabbit Alexa Fluor 555-
conjugated secondary antibodies in blocking buffer at RT. CNS tissue
sections were obtained fromWT and Irf7/mice after cardiac perfusion
with 4% paraformaldehyde. Tissues were frozen, blocked, and stained
with the primary and secondary antibodies listed above as previously de-
scribed (47). Nuclei in all preparations were stained with Topro3. All
images were acquired via confocal microscopy (Carl Zeiss USA). Colocal-
ization statistics were obtained via analysis with ImageJ software.
ELISA. Sandwich ELISA kits were used for detection of cytokine levels
in cell culture supernatants. ELISA kits for IFN- and IFN- (PBL Inter-
feronSource), TNF- (EBioscience), and IL-1 (R&DSystems)were used
according to the manufacturers’ instructions. Colorimetric reading of
ELISA plates was performed with a Synergy H1 microplate reader and
Gen5 software (BioTek Instruments, Inc.).
Virus inactivation. Stocks of WNV (NY-2000, 2104 PFU/ml) were
incubated in 0.1% (vol/vol) -propiolactone (Sigma) for 30 min at 4ºC.
BPL in viral stocks was then inactivated by incubating the stocks for 2 h at
37ºC, followed by hydrolysis of BPL via subsequent overnight incubation
at 4ºC. Alternatively, similar stocks were placed in 35-mm2 culture plates
and incubated in a dark chamber above a UV transilluminator box (Strat-
agene) for 2 h at RT. Inactivated viral stocks were stored at80ºC.
Neutralizing-antibody studies. Neutralizing-antibody studies were
performed after 2 h of pretreatment with purified anti-mouse TNF-
(1 g/ml, clone TN3-19; EBioscience) and anti-mouse IL-1 (1 g/ml,
clone B122; Leinco) antibodies. IgG isotype antibodies were used as neg-
ative controls.
GTPase studies.GTPase pulldown experiments were performed with
an activated Rac1/RhoA/CDC42Rhotekin and PAK agarose bead kit (Cell
BioLabs, Inc.) according to the manufacturer’s instructions. Purified,
GTP-bound protein and unpurified BMEC protein lysates were separated
via gel electrophoresis on 10% bis-Tris gels (Invitrogen) and transferred
onto iBlot nitrocellulose transfer membranes (Invitrogen) according to
standard protocols. Blots were probed with primary antibodies against
Rac1, RhoA, and CDC42 (Cell Biolabs), followed by incubation with
IRDye-conjugated secondary antibodies (LI-COR). Blots were imaged
with the Odyssey fluorescent scanning system (LI-COR). TEER and viral
trafficking experiments involving inhibition of GTPase signaling were
performed as previously described (68), with in vitro BBBs after 2 h of
pretreatment in the top chamber at 37ºC with the following agents: the
Rac1 inhibitor Z62954982 (1 mM; Cayman Chemical Co.), the Rho/
ROCK inhibitor H-1152P (10 nM; Cayman Chemical Co.), and the
CDC42 inhibitor ML141 (100 nM; Tocris-R&D Systems).
Statistical analysis.All of the data reportedhere aremean values	 the
standard errors of the means. Data reported for in vitro TEER and cyto-
kine expression experiments include 6 to 12 replicates from two or three
independent experiments. In vitro ICC analyses include five or six repli-
cates from two independent experiments. In vivo fluorescein experiments
included six mice/group/day from two independent experiments. In vivo
IHC analyses included fivemice/group/day from two independent exper-
iments. All group effects were compared via one- or two-way analysis of
variance; Bonferroni’s post hoc test was subsequently used to compare
individual means. Correction for repeated measures was also used where
appropriate. All statistical analysis was performed with GraphPad Prism
software (v 5.0). P 0.05 was considered significant for all comparisons.
Statistical significance is indicated as follows: *,P 0.05; **,P 0.01; ***,
P 0.001.
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